OBJECTIVES: This study sought to investigate predictors and safety of next-day discharge (NDD) after transcatheter aortic valve replacement (TAVR). BACKGROUND: Information about predictors and safety of NDD after TAVR is limited. METHODS: The study reviewed 663 consecutive patients who underwent elective balloon-expandable TAVR (from July 2014 to July 2016) at our institution. We first determined predictors of NDD in patients who underwent minimalist transfemoral TAVR. After excluding cases with complications, we compared 30-day and 1-year outcomes between NDD patients and those with longer hospital stay using Cox regression adjusting for the Predicted Risk of Mortality provided by the Society of Thoracic Surgeons. The primary endpoint was the composite of mortality and readmission at 1 year. RESULTS: A total of 150 patients had NDD after TAVR and 210 patients had non-NDD. Mean age and the Society of Thoracic Surgeons Predicted Risk of Mortality were 80.7 ± 8.8 years and 6.6 ± 3.7%, respectively. Predictors of NDD were male sex (odds ratio [OR]: 2.02; 95% confidence interval [CI]: 1.28 to 3.18), absence of atrial fibrillation (OR: 1.62; 95% CI: 1.02 to 2.57), serum creatinine (OR: 0.71; 95% CI: 0.55 to 0.92), and age (OR: 0.95; 95% CI: 0.93 to 0.98). As expected, 84% of patients with complications had non-NDD. After excluding cases with complications, there was no difference in hazard rates of the 30-day composite outcome between NDD and non-NDD (hazard ratio: 0.62; 95% CI: 0.20 to 1.91), but the hazard of the composite outcome at 1 year was significantly lower in the NDD group (hazard ratio: 0.47; 95% CI: 0.27 to 0.81). This difference in the composite outcome can be explained by the lower hazard of noncardiovascular related readmission in the NDD group. CONCLUSIONS: Factors predicting NDD include male sex, absence of atrial fibrillation, lower serum creatinine, and younger age. When compared with patients without complications with a longer hospital stay, NDD appears to be safe, achieving similar 30-day and superior 1-year clinical outcomes.
OBJECTIVES: This study sought to investigate predictors and safety of next-day discharge (NDD) after transcatheter aortic valve replacement (TAVR). BACKGROUND: Information about predictors and safety of NDD after TAVR is limited. METHODS: The study reviewed 663 consecutive patients who underwent elective balloon-expandable TAVR (from July 2014 to July 2016) at our institution. We first determined predictors of NDD in patients who underwent minimalist transfemoral TAVR. After excluding cases with complications, we compared 30-day and 1-year outcomes between NDDpatients and those with longer hospital stay using Cox regression adjusting for the Predicted Risk of Mortality provided by the Society of Thoracic Surgeons. The primary endpoint was the composite of mortality and readmission at 1 year. RESULTS: A total of 150 patients had NDD after TAVR and 210 patients had non-NDD. Mean age and the Society of Thoracic Surgeons Predicted Risk of Mortality were 80.7 ± 8.8 years and 6.6 ± 3.7%, respectively. Predictors of NDD were male sex (odds ratio [OR]: 2.02; 95% confidence interval [CI]: 1.28 to 3.18), absence of atrial fibrillation (OR: 1.62; 95% CI: 1.02 to 2.57), serum creatinine (OR: 0.71; 95% CI: 0.55 to 0.92), and age (OR: 0.95; 95% CI: 0.93 to 0.98). As expected, 84% of patients with complications had non-NDD. After excluding cases with complications, there was no difference in hazard rates of the 30-day composite outcome between NDD and non-NDD (hazard ratio: 0.62; 95% CI: 0.20 to 1.91), but the hazard of the composite outcome at 1 year was significantly lower in the NDD group (hazard ratio: 0.47; 95% CI: 0.27 to 0.81). This difference in the composite outcome can be explained by the lower hazard of noncardiovascular related readmission in the NDD group. CONCLUSIONS: Factors predicting NDD include male sex, absence of atrial fibrillation, lower serum creatinine, and younger age. When compared with patients without complications with a longer hospital stay, NDD appears to be safe, achieving similar 30-day and superior 1-year clinical outcomes.
Authors: Shara S Azad; Frederick C Cobey; Lori Lyn Price; Roman Schumann; Alexander D Shapeton Journal: J Cardiothorac Vasc Anesth Date: 2020-05-15 Impact factor: 2.628
Authors: Abdulaziz A Asbeutah; Muhammad Junaid; Fatima Hassan; Jesus Avila Vega; Nephertiti Efeovbokhan; Rami N Khouzam; Uzoma N Ibebuogu Journal: World J Cardiol Date: 2022-05-26
Authors: Elizabeth M Perpetua; Kimberly A Guibone; Patricia A Keegan; Roseanne Palmer; Martina K Speight; Kornelija Jagnic; Joan Michaels; Rosemarie A Nguyen; Emily S Pickett; Dianna Ramsey; Susan J Schnell; Shing-Chiu Wong; Mark Reisman Journal: Struct Heart Date: 2022-03-21
Authors: Sandra B Lauck; Suzanne J Baron; William Irish; Britt Borregaard; Kimberly A Moore; Candace L Gunnarsson; Seth Clancy; David A Wood; Vinod H Thourani; John G Webb; Harindra C Wijeysundera Journal: J Am Heart Assoc Date: 2021-09-28 Impact factor: 5.501
Authors: Madeleine Barker; Janarthanan Sathananthan; Emily Perdoncin; Chandan Devireddy; Patricia Keegan; Kendra Grubb; Andrei M Pop; Jeremiah P Depta; Devesh Rai; Farhad Abtahian; Mark S Spence; Jonathan Mailey; Douglas F Muir; Mark J Russo; Jennifer Pineda-Salazar; Alexis Okoh; Meghan Smith; Thom G Dahle; Masud Rana; Mesfer Alfadhel; David Meier; Andrew Chatfield; Mariama Akodad; Anthony Chuang; Rohit Samuel; Thomas Nestelberger; Cameron McAlister; Sandra Lauck; John G Webb; David A Wood Journal: JACC Cardiovasc Interv Date: 2022-03-28 Impact factor: 11.195